This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (8)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: We commend Dr Hulley and colleagues¹ on a well-designed, first-ever randomized trial to evaluate continuous estrogen-progestin hormone replacement therapy (HRT) for the secondary prevention of coronary heart disease (CHD). Surprisingly and disturbingly, the results do not support the beneficial effects of HRT found in observational studies.

Despite the appropriate randomization, blinding, and intention-to-treat analysis, we are concerned that, during the trial, subjects in the control and HRT groups were differently exposed to agents that could affect the primary study outcomes. For example, the authors noted that more women in the control group began treatment with lipid-lowering agents (primarily statins) during the trial, and they astutely adjusted for low-density lipoprotein levels during their analysis. However, since statin use over an average of 5 years decreases coronary events and coronary deaths in patients with CHD who have high and normal cholesterol levels,^2-4 this differential utilization could still bias the . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women
, , , , , , , and
JAMA. ;280():605-613.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effect of Estrogen Plus Progestin on Progression of Carotid Atherosclerosis in Postmenopausal Women With Heart Disease: HERS B-Mode Substudy
Byington et al.
Arterioscler. Thromb. Vasc. Bio. 2002;22:1692-1697.
ABSTRACT | FULL TEXT  

Risk of Recurrent Coronary Events in Relation to Use and Recent Initiation of Postmenopausal Hormone Therapy
Heckbert et al.
Arch Intern Med 2001;161:1709-1713.
ABSTRACT | FULL TEXT  

Effects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis
Herrington et al.
NEJM 2000;343:522-529.
ABSTRACT | FULL TEXT  

Estrogen and Progestin, Lipoprotein(a), and the Risk of Recurrent Coronary Heart Disease Events After Menopause
Shlipak et al.
JAMA 2000;283:1845-1852.
ABSTRACT | FULL TEXT  

Hormone therapy: time for replacement?
Herrington and Furberg
Eur Heart J 1999;20:1285-1286.